0001638234-17-000001.txt : 20170405 0001638234-17-000001.hdr.sgml : 20170405 20170405151422 ACCESSION NUMBER: 0001638234-17-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170405 DATE AS OF CHANGE: 20170405 EFFECTIVENESS DATE: 20170405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acer Therapeutics Inc. CENTRAL INDEX KEY: 0001638234 IRS NUMBER: 320426967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-284133 FILM NUMBER: 17742328 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-922-3600 MAIL ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 D 1 primary_doc.xml X0707 D LIVE 0001638234 Acer Therapeutics Inc. 222 THIRD STREET, SUITE 2240 CAMBRIDGE MA MASSACHUSETTS 02142 844-902-6100 DELAWARE None None Corporation true 2013 Christopher Schelling c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Promoter Stephen Aselage c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director John Dunn c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Luc Marengere c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Harry Palmin c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Promoter Pharmaceuticals Decline to Disclose 06b false 2017-03-22 false true true false 0 5500000 3125000 2375000 false 4 0 0 419000 true The Issuer expects to use approximately $419,000 of the proceeds for salary and other compensation to the Issuer's executive officers, directors and promoters during the remaining 2017 fiscal year. false Acer Therapeutics Inc. /s/ Christopher Schelling Christopher Schelling President & CEO 2017-04-05